Aura Biosciences Inc is a clinical-stage biotechnology company focused on developing precision therapies to treat solid tumors while preserving organ function. The company's lead product candidate bel-sar is a virus-like drug conjugate designed for targeted cancer therapy with minimal damage to healthy tissues. Aura Biosciences operates in the biotechnology and pharmaceutical industry, concentrating on oncology indications with initial emphasis on ocular and urologic cancers.

Aura Biosciences generates revenue through the development and potential commercialization of its product candidates, primarily bel-sar, which is being evaluated in multiple clinical trials for indications such as early choroidal melanoma, metastases to the choroid, cancers of the ocular surface, and non-muscle-invasive bladder cancer. The company does not currently have approved products on the market and relies on funding from investors, partnerships, and potential future milestone payments or royalties from licensing agreements. Revenue generation is anticipated upon regulatory approval and successful market entry of its therapeutic candidates.

The company operates through the following segments: ocular oncology and urologic oncology.

• The ocular oncology segment focuses on the development of bel-sar for treating early choroidal melanoma, metastases to the choroid, and cancers of the ocular surface. This segment leverages the company's virus-like drug conjugate technology to deliver targeted therapy that aims to preserve vision and ocular structures while achieving tumor control. Clinical programs include the global Phase 3 CoMpass trial for early choroidal melanoma, an ongoing Phase 2 trial for metastases to the choroid, and a planned Phase 1 proof-of-concept trial for ocular surface cancers.

• The urologic oncology segment is dedicated to advancing bel-sar for the treatment of bladder cancer, beginning with non-muscle-invasive bladder cancer (NMIBC). This segment evaluates bel-sar as a potential immune-based, organ-sparing therapy to reduce recurrence and progression risk. Activities include an ongoing Phase 1b/2 trial assessing additional doses and cycles in intermediate and high-risk NMIBC patients, building on positive Phase 1 data and FDA Fast Track Designation received in 2022.

Aura Biosciences positions itself as an innovator in the oncology space with a novel class of therapeutics called virus-like drug conjugates (VDCs), which offer a dual mechanism of action involving direct tumor cell killing and activation of antitumor immunity. The company faces competition from established pharmaceutical and biotechnology firms developing treatments for ocular and urologic cancers, including companies such as Immunocore, Ideaya Biosciences, CG Oncology, and UroGen Pharma. However, Aura Biosciences differentiates itself through its bel-sar platform's potential to preserve organ function, its favorable safety profile observed in clinical trials, and its applicability across multiple solid tumor types due to its tumor-targeting mechanism involving modified heparan sulfate proteoglycans.

Aura Biosciences serves patients and healthcare providers in the oncology space, particularly those affected by ocular and urologic cancers. The company's therapies are intended for use by ocular oncologists and urologists in clinical settings such as hospitals and specialty clinics. While specific customer names are not disclosed in the filing, the company targets medical professionals treating conditions like early choroidal melanoma, metastases to the choroid, ocular surface cancers, and non-muscle-invasive bladder cancer.